Home › Compare › ORPHY vs GBDC

ORPHY vs GBDC: Dividend Comparison 2026

ORPHY yields 6666.67% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812041.13M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ORPHY vs GBDC

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ORPHY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,812,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + GBDC for your $10,000?

ORPHY: 50%GBDC: 50%
100% GBDC50/50100% ORPHY
Portfolio after 10yr
$514047673906041.38M
Annual income
$499,314,272,668,141,600,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ORPHY
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
GBDC buys
0
No recent congressional trades found for ORPHY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYGBDC
Forward yield6666.67% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$1028095347812062.00M ✓$20.85M
Annual income after 10y$998,628,545,336,266,700,000.00 ✓$16,450,733.83
Total dividends collected$1026118102492338.88M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ORPHY vs GBDC ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$677,367$666,666.67$12,492$1,791.70+$664.9K → ORPHY
2$42,928,313$42,203,530.63$16,527$3,160.58+$42.91M → ORPHY
3$2,545,616,701$2,499,683,405.64$23,588$5,904.90+$2545.59M → ORPHY
4$141,255,910,403$138,532,100,533.89$37,141$11,901.65+$141255.87M → ORPHY
5$7,335,374,338,812$7,184,230,514,680.15$66,205$26,463.38+$7335374.27M → ORPHY
6$356,516,885,536,661$348,668,034,994,132.70$137,452$66,612.65+$356516885.40M → ORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$342,372$195,298.53+$16218956689.62M → ORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$1,053,292$686,954.33+$690711023144.82M → ORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$4,111,439$2,984,416.95+$27539067734383.87M → ORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$20,849,974$16,450,733.83+$1028095347812041.13M → ORPHY

ORPHY vs GBDC: Complete Analysis 2026

ORPHY — Stock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ORPHY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.